CALQUENCE®▼ (acalabrutinib)

CALQUENCE® (acalabrutinib) est un inhibiteur de la Tyrosine
Kinase de Bruton pour le traitement de la leucémie lymphoïde chronique (LLC).1

Equipe

Vos personnes de contacts

 

 

Margot Peeters
Hospital Representative Hematology
& Gastrointestinal Oncology Flanders

Joke Van Den Berge
Hospital Representative Hematology
& Gastrointestinal Oncology Flanders

Stéphane Lemaire
Hospital Representative
Hematology
& Gastrointestinal Oncology 
Wallonia & Luxembourg

Véronique Petit
Hospital Representative
Hematology
& Gastrointestinal Oncology Wallonia

Evelien Van Schoor
Medical Advisor
Hematology

 

 

L'équipe élargie d'hématologie

 

 

Tom Ghysels
Business Unit Director
Oncology

Joeri Van op den Bosch
Franchise Lead 
Hematology
& Gastrointestinal Oncology

Thierry Marysael
Medical Affairs Lead
Hematolog/Breast
& ovarian cancer

Maureen Van Well
Government Affairs &
Market Access Lead
Oncology

Tine Cuppens
Medical Affairs
Manager Hematology

Zakaria Bouzaiane
Brand Manager
Hematology
& Gastrointestinal Oncology

Marieke Siemons
First Line Sales Manager
Hematology
& Gastrointestinal Oncology